Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.

@article{Balducci2014RetrospectiveAO,
  title={Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.},
  author={Lodovicco Balducci and May Mo and Esteban Abella and Alan Saven},
  journal={American journal of clinical oncology},
  year={2014},
  volume={37 6},
  pages={603-10}
}
OBJECTIVES To evaluate primary prophylaxis with pegfilgrastim, a recombinant human granulocyte colony-stimulating factor, on maintaining relative dose intensity (RDI) in patients with non-Hodgkin lymphoma (NHL) receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-rituximab (CHOP-R). METHODS This retrospective analysis pooled data from pegfilgrastim NHL clinical trials. Patients received up to 6 cycles of CHOP/CHOP-R every 2 (Q2W) or 3 (Q3W) weeks. RDI and the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
6 Citations
37 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 37 references

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology ( NCCN Guidelines s ) . Non - Hodgkin ’ s Lymphoma . v 3 .

  • RI Fisher, ER Gaynor, S Dahlberg
  • 2011

Similar Papers

Loading similar papers…